Convalescent Plasma News and Research

RSS

Spike protein mutations in SARS-CoV-2 variants help resist antibody neutralization

Researchers based in Beijing and Shenzhen, China, report that they have identified mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may allow variant strains to avoid neutralization by monoclonal antibodies and convalescent blood plasma.

11 Mar 2021

Researchers develop assay for qualitative assessment of SARS-CoV-2 neutralizing antibodies

To address the need for a high-quality neutralization assay against SARS-CoV-2, researchers from the NIAID modified and optimized a previously established fluorescence reduction neutralization assay (FRNA) to provide a quantitative assessment of a large number of infected cells through the use of a high-content imaging system.

11 Mar 2021

Researcher find an emergent SARS-CoV-2 variant in California

Researchers have found a new SARS-CoV-2 variant in California, USA. This variant is more transmissible than circulating strains but slightly less transmissible than the new N501Y variant and moderately resistant to antibodies in convalescent sera and mRNA vaccines.

10 Mar 2021

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

A monoclonal antibody "cocktail" developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published in the journal Nature Medicine.

5 Mar 2021

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Researchers in the United States say the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant – P.1 – that has recently emerged in Brazil shows a worrying level of resistance to neutralization by antibodies.

4 Mar 2021

Delayed detection of oral fluid anti-SARS-CoV-2 antibodies increases the time to viral clearance

A prospective observational study has revealed that the late appearance of anti-SARS-CoV-2 antibodies in oral fluid, absence of fever as an early symptom, and elevated BMI are associated with delayed clearance of viral RNA in mild to moderate COVID-19 patients.

4 Mar 2021

Study reports persistent SARS-CoV-2 with increasing viral variants in pediatric patients

New research, published on medRxiv preprint server, has reported the effect of prolonged SARS-CoV-2 infection in immunocompromised children and young adults.

4 Mar 2021

Early antibody response predicts COVID-19 outcome

To address this gap, researchers from the U.S. evaluated the timing of antibody production against SARS-CoV-2 in hospitalized patients. They used a highly sensitive multiplexed bead-based immunoassay that allows for early detection of anti-SARS-CoV-2 antibodies. The study is published on the preprint server medRxiv.

2 Mar 2021

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

Researchers at the New York State Department of Health in the United States have said concerning mutations within the B.1.526 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently become prevalent in New York State warrant further monitoring.

2 Mar 2021

Could small synthetic antigen proteins be diagnostic tools for SARS-CoV-2?

Researchers have developed small proteins from sequences in SARS-CoV-2's RBD that bind to ACE2. These were as effective in binding to neutralizing antibodies as larger RBD proteins.

2 Mar 2021

New SARS-CoV-2 B.1.526 variant emerges in New York

New York has the first case of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant called B.1.526, picked up by genomic surveillance research from Columbia University. The findings come after reports of other variants have been reported worldwide — B.1.1.7 in the United Kingdom, B.1.351 in South Africa, and P.1/P.2 in Brazil.

28 Feb 2021

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

A new study deals with the clinical and virological effects of circulating SARS-CoV-2 variants, especially as they affect vaccine efficacy.

26 Feb 2021

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

A new study by a team of researchers in the UK and US describes the use of a computational tool that generates all possible single amino acid substitutions in SARS-CoV-2 and predicts their effects.

26 Feb 2021

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers have developed a stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21) against SARS-CoV-2 infection in Syrian hamsters. They demonstrated the high therapeutic efficacy of this homotrimeric Nb, leveraging both intranasal and aerosol delivery.

26 Feb 2021

Researchers investigate the duration of the immune response to SARS-CoV-2

The optimal timeframe for donating convalescent plasma for use in COVID-19 immunotherapy, which was given emergency use authorization by the Food and Drug Administration in August 2020, is within 60 days of the onset of symptoms, according to a new Penn State-led study.

26 Feb 2021

Study reports lasting immune response in convalescent COVID-19 patients

Researchers report the cellular immune response of convalescent patients in Germany, who recovered from mild or moderate infection compared to that of healthy people with no history of COVID-19.

25 Feb 2021

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Researchers report on a Chicken-derived antibody against SARS-CoV-2, offering preliminary data on a potential therapeutic for COVID-19 warranting further research.

19 Feb 2021

How does the SARS-CoV-2 E484K mutation increase viral fitness?

How do mutations benefit SARS-CoV-2? To explore this, a team of researchers from China took a closer look at the physical interactions that occur between the proteins after viral mutation.

19 Feb 2021

Convalescent plasma shows CD8+ T cell responses to SARS-CoV-2 variants

Researchers in the United States have conducted a study suggesting that individuals who have recovered from or been vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should maintain effective CD8+ T-cell responses against the major variants that have recently emerged.

17 Feb 2021

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

A new preprint research paper posted to the bioRxiv server provides a greater understanding of the aspect of humoral immunity against the virus – the plasma cells that pour out a flood of specific antibodies targeting various epitopes on the pathogen.

16 Feb 2021

Convalescent Plasma News and Research

Spike protein mutations in SARS-CoV-2 variants help resist antibody neutralization

Researchers develop assay for qualitative assessment of SARS-CoV-2 neutralizing antibodies

Researcher find an emergent SARS-CoV-2 variant in California

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Delayed detection of oral fluid anti-SARS-CoV-2 antibodies increases the time to viral clearance

Study reports persistent SARS-CoV-2 with increasing viral variants in pediatric patients

Early antibody response predicts COVID-19 outcome

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

Could small synthetic antigen proteins be diagnostic tools for SARS-CoV-2?

New SARS-CoV-2 B.1.526 variant emerges in New York

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers investigate the duration of the immune response to SARS-CoV-2

Study reports lasting immune response in convalescent COVID-19 patients

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

How does the SARS-CoV-2 E484K mutation increase viral fitness?

Convalescent plasma shows CD8+ T cell responses to SARS-CoV-2 variants

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News